Meet Dr. Adrian Waring
Adrian has planted deep roots in the CRO industry.
At the University of Wales, Adrian earned his BSc. degree in biochemistry. It was here he became interested in xenobiotic metabolism, which simply put, is how biological systems deal with foreign compounds, such as drugs and pesticides, they encounter. Radiolabelled tracers are essential for this work to enable the biotransformation of the molecule to be followed. He still enjoys identifying novel metabolites.
Adrian’s Ph.D. studies centered on metabolism as a mechanism for herbicide selectivity and the use of cell cultures as a metabolic model for whole plants. His early career was spent in environmental fate, which involves conducting small- scale lab studies to investigate the fate and behavior of xenobiotics in soil, sediment and water. This has been a strong growth area in metabolism. When Adrian started in the industry in the mid-1980s, this work was predominantly performed on compounds that are deliberately introduced into the environment, such as pesticides. Today, environmental risk assessments are needed on a variety of different molecules that enter the environment, including pharmaceuticals, veterinary products, biocides and industrial chemicals.
Now with thirty years of industry experience under his belt—Lean Sigma Master Black Belt, that is—he is focused on the growth of all areas of the metabolism business and driving operational efficiency to ensure delivery of high-quality, cost-effective and on-time studies for our partners.
As Director of Metabolism at Pharmaron, he leads the radiolabelled metabolism team to provide solutions in the areas of drug disposition, including non-clinical QWBA, MARG and in vitro ADME, clinical drug metabolism and pharmacokinetics to support clinical studies and regulatory NDA submission using radiolabelled test articles. In addition, his team offers services in evaluating environmental fate for the chemical, crop protection, human and animal healthcare industries.
Adrian notes that it’s an exciting time for the metabolism group.
“As we develop integrated services with other parts of the rapidly growing Pharmaron organization, we are adapting our service offerings to meet the needs of partners working with new therapies, such as oligonucleotides, ADCs and other biologics. Science and technology in key areas of metabolism, such as drug-drug interactions (DDIs) and drug transporters, are advancing rapidly and our services need to continually evolve to keep pace with regulatory thinking.”
About Dr. Adrian Waring
Adrian is the Director of Metabolism at Pharmaron (formerly Quotient Bioresearch) at the Rushden, UK facility. Prior to Pharmaron, he worked at Covance and Envigo. He received his Ph.D. in biochemistry from the University of London. He is a certified Lean Sigma Master Black Belt. In his spare time, Adrian roots for Peterborough United, his home town football team. He’s been a loyal fan since childhood and is hopeful that one day Peterborough United (“The Posh”) will play in the Premier League.
Learn more about our radiolabelled science services
